EGFR gene mutation+1
Not recruitingStudy on Amivantamab, Lazertinib, and Bevacizumab for Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer After Treatment Progression
Study on Amivantamab, Lazertinib, and Bevacizumab for Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer After Treatment Progression
- Disease:EGFR gene mutationNon-small cell lung cancer
- Substances:AmivantamabBevacizumab+1
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Amivantamab
- Sponsor:ETOP IBCSG Partners Foundation









